• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·ODYY
Share

Odyssey Health, Inc. Stocks

$ 0Last Updated 29.07.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

$ 605812

$ 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Odyssey Health, Inc. operates as a medical enterprise, primarily focused on the innovation and development of diverse healthcare products. Its current portfolio encompasses CardioMap, an advanced device for cardiac monitoring and screening, alongside the "Save A Life" line of devices engineered for choking emergencies. Additionally, the company is advancing neurosteroid drug compounds, PRV-001 and PRV-002, intended for the treatment of concussive injuries and various rare brain disorders. The organization, established in 2014 and headquartered in Las Vegas, Nevada, was previously known as Odyssey Group International, Inc.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is of fair value on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

31.07.2026 09:00

Ferrari Raises Annual Forecast Thanks to Demand for Limited-Edition Models

31.07.2026 03:07

Apple shares fell after a weak forecast. Sales will be affected by a shortage of memory chips

31.07.2026 02:45

It's the best day for chipmakers since 2025. Burry is shorting them again.

31.07.2026 01:43

Amazon reported accelerated revenue growth in its cloud business. Its stock jumped 9%.

31.07.2026 01:27

Microsoft Beat Nvidia's Record for Market Capitalization Growth

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026